Development Strategy
Propanc’s strategy for the development of its technology is to undertake early stage non-clinical and clinical development of its drug products through to a significant value inflexion point.
Such value inflexion points in the context of cancer drugs are typically at the point where formal, controlled clinical trials have demonstrated ‘proof of concept’ – typically meaning that there is controlled clinical trial evidence that the drug is effective in the proposed target patient population, has an acceptable safety profile, and is suitable for further development.
As part of that commercial strategy, Propanc will:
- Continue research and development to build our existing intellectual property portfolio, and to seek new, patentable discoveries;
- Seek to ensure all product development is undertaken in a manner that makes its products approvable in the major pharmaceutical markets, including theU.S., Europe, the UK and Japan;
- Aggressively pursue the protection of our technology through all means possible, including patents in all major jurisdictions, and potentially trade secrets;
- Acquire new targets: We will investigate opportunities to acquire new targets which complement our future goals and expand our products and services within related healthcare fields.